Replies to post #246168 on Biotech Values

[dewophile]

The government subsidized the GSK antibiotic I think and they may make a purchase to stock it for plague. Overall hard to make money in antibiotics for all the reasons you mention. Z-pak and cubicin are exceptions not the norm. GSK sold most of their antibiotics to generics years ago. I was surprised they did nearly 600M in branded antibiotic sale last year.

[DewDiligence]

The whole antibiotics development paradigm is deeply problematic.

Congress is aware of the problem and there is bipartisan support for change, but political gridlock has prevented lawmakers from getting anything concrete accomplished.

[dewophile]

Data for GSKs antibiotic program out today. They met superiority in one of the trials. Not sure if this would change your opinion regarding the commercial potential for the drug. I’m honestly not sure how to value the program I largely share your sentiment regarding antibiotics. The days of mega blockbusters like cubicin and z-pak are probably over but wondering if this could still bring in some decent revenue esp if they can market on superiority to certain subgroups

https://www.gsk.com/en-gb/media/press-releases/gepotidacin-s-positive-phase-iii-data-shows-potential-to-be-the-first-in-a-new-class-of-oral-antibiotics-for-uncomplicated-urinary-tract-infections/

[DewDiligence]

(PFE)—Apropos to antibiotics:

https://www.businesswire.com/news/home/20230601005216/en